Janssen Phase 3 study on combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisonedoes not show significant benefit
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the ...
Read more